TYW2 and colorectal cancer: However, when subdivided by stages, colorectal cancer patients with early-stage disease (n = 184, stage I and II) harboring TYW2 epigenetic inactivation showed significantly reduced overall survival (hazard ratio [HR] = 2.984; 95% confidence interval [CI] = 1.26 to 7.08; P = 0.009, log-rank test) (Fig. 4A).